TG Therapeutics Q4 EPS Seen at $0.35 on $189.4M Revenue Forecast
TG Therapeutics is expected to report Q4 EPS of $0.35, up 133.3% year-over-year, on projected revenues of $189.4 million, a 75.1% increase from Q4 last year. However, analysts have cut Q4 EPS forecasts by 12.9% over the past month, yielding an Earnings ESP of -12.43% and a Zacks Rank #3, suggesting an earnings beat is unlikely.
1. Expected Q4 Results
TG Therapeutics is forecast to post Q4 EPS of $0.35 per share, representing a 133.3% increase year-over-year, on revenues of $189.4 million, up 75.1% from the fourth quarter of last year.
2. Estimate Revision Trends
Over the past 30 days, the consensus EPS estimate for Q4 has been revised down by 12.93%, reflecting analyst reassessments of growth prospects during the period.
3. Earnings ESP Analysis
The most accurate estimate now sits below the consensus, producing an Earnings ESP of -12.43%; combined with a Zacks Rank #3, this indicates a low probability of an upside earnings surprise.
4. Historical Surprise Context
In the last reported quarter, the company delivered a +912.5% EPS surprise, posting $2.43 versus $0.24 expected, and has beaten consensus estimates in two of the past four quarters.